Tag Archives: biotechnology appeal

Ignorance is Bliss – for Teva

I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that … Continue reading

Posted in Obviousness | Tagged , , , , , , , , , , , | 1 Comment

CLS v. Alice Bank And The Cult Of The “Abstract Idea”

Ex-Judge Michel’s compelling amicus brief – more on that in a future post—prompted me to take a quick look back at the evolution “abstract idea” as a patent-ineligible category of invention. This category of patent-ineligible invention is listed, along with … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , , , , , , , | Leave a comment

Wyeth v. Abbott Labs. – Picking Plaintiff’s Poison

In July of 2011, I wrote a post for this blog on BSC v. J&J, a Fed. Cir. decision in which four J&J patents claiming stents eluting rapamycin, a drug that inhibits restenosis after balloon angioplasty, were held invalid for … Continue reading

Posted in Enablement, Written Description Requirements (WDR) | Tagged , , , , , , , , , , | 1 Comment

Divided Panel Finds DNA Molecules Patentable – Cancer Screening Claims Too Abstract

Today a divided Fed. Cir. panel of Judges Lourie, Moore and Bryson – Lourie writing for the “majority” – reversed the district court judge, in AMP v. Myriad, holding that isolated DNA sequences are patent-eligible subject matter and not natural … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , , , , , , , , | Leave a comment